Aprea Therapeutics (APRE) Corporate presentation summary

Strategic focus and pipeline

• Focused on precision medicine and synthetic lethality to develop targeted therapies for biomarker-defined cancers, aiming to replace broad chemotherapy with safer, more selective treatments.

• Pipeline includes WEE1 inhibitor (APR-1051) and ATR inhibitor (ATRN-119), both advancing through clinical development with milestones set through 2026.

• Programs target significant unmet needs in genetically defined cancer populations, with early clinical proof-of-concept demonstrated.

Clinical development and data

• APR-1051, a next-generation WEE1 inhibitor, shows a potentially wider therapeutic window and improved tolerability compared to earlier agents.

• Phase 1 study design includes dose escalation and optimization in patients with advanced solid tumors harboring specific gene alterations.

• Early clinical data show partial responses and durable stable disease in heavily pretreated patients with PPP2R1A-mutated endometrial cancer, FBXW7-mutated colorectal cancer, and HPV+ head and neck cancers.

• Treatment-related adverse events were mostly mild, with minimal grade ≥3 toxicities observed.

Differentiation and preclinical insights

• APR-1051 is structurally differentiated, highly selective for WEE1, and demonstrates minimal off-target inhibition of PLK1, PLK2, or PLK3, potentially reducing toxicity.

• Preclinical studies show activity in combination with chemotherapy and immunotherapy across multiple cancer models.

• Minimal PLK1 co-inhibition enables full therapeutic potential of APR-1051, as PLK1 suppression is linked to adverse effects.